2015 Dec 14. pii: 201522364. [Epub ahead of print]
Ogasawara D1, Deng H2, Viader A1, Baggelaar MP2, Breman A2, den Dulk H2, van den Nieuwendijk AM3, Soethoudt M2, van der Wel T2, Zhou J2, Overkleeft HS3, Sanchez-Alavez M1, Mo S1, Nguyen W1, Conti B1, Liu X4, Chen Y4, Liu QS4, Cravatt BF5, van der Stelt M6.
Abstract
Diacylglycerol lipases (DAGLα and DAGLβ) convert diacylglycerol to the endocannabinoid 2-arachidonoylglycerol. Our understanding of DAGL function has been hindered by a lack of chemical probes that can perturb these enzymes in vivo. Here, we report a set of centrally active DAGL inhibitors and a structurally related control probe and their use, in combination with chemical proteomics and lipidomics, to determine the impact of acute DAGL blockade on brain lipid networks in mice. Within 2 h, DAGL inhibition produced a striking reorganization of bioactive lipids, including elevations in DAGs and reductions in endocannabinoids and eicosanoids. We also found that DAGLα is a short half-life protein, and the inactivation of DAGLs disrupts cannabinoid receptor-dependent synaptic plasticity and impairs neuroinflammatory responses, including lipopolysaccharide-induced anapyrexia. These findings illuminate the highly interconnected and dynamic nature of lipid signaling pathways in the brain and the central role that DAGL enzymes play in regulating this network.
KEYWORDS:
endocannabinoid; inhibitor; lipase; nervous system
- PMID:
- 26668358
- [PubMed – as supplied by publisher]